| Code | CSB-RA001670MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Bempikibart, targeting the interleukin-7 receptor (IL7R), also known as CD127. IL7R is a type I transmembrane protein that forms part of the receptor complex for interleukin-7, a critical cytokine involved in T cell and B cell development, homeostasis, and survival. The receptor plays a pivotal role in maintaining lymphocyte populations and regulating immune responses. Dysregulation of IL7R signaling has been implicated in various autoimmune and inflammatory conditions, including multiple sclerosis, inflammatory bowel disease, and primary immunodeficiencies.
Bempikibart is a therapeutic antibody designed to modulate IL7R activity and has been investigated for its potential in treating autoimmune disorders by interfering with pathogenic T cell survival and activation. This biosimilar antibody provides researchers with a valuable tool for investigating IL7R-mediated signaling pathways, studying lymphocyte biology, and exploring immune system dysfunction in disease models. It serves as an important reagent for immunological research and therapeutic mechanism studies.
There are currently no reviews for this product.